Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE

Autor: San-Miguel, JF, Avet-Loiseau, H, Paiva, B, Kumar, SK, Dimopoulos, MAA, Facon, T, Mateos, M-V, Touzeau, C, Jakubowiak, AJ, Usmani, SZ, Cook, G, Cavo, M, Quach, H, Ukropec, J, Ramaswami, P, Pei, H, Qi, M, Sun, S, Wang, J, Krevvata, M, DeAngelis, N, Heuck, C, Van Rampelbergh, R, Kudva, A, Kobos, R, Bahlis, NJ

In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone; D-Rd) and 58% in ALCYONE (daratumumab/bortezomib/melp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::04aa18714d279dc6478c80ac17290cab

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM)

Autor: Krishnan, AY, Garfall, AL, Mateos, MV, van de Donk, NWCJ, Nahi, H, San-Miguel, JF, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, LX, Verona, R, Girgis, S, Stephenson, T, Goldberg, JD, Banerjee, A, Usmani, SZ

Publikováno v: Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::8d76099a4eecef2586ede6c45f26c967
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2031

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/ Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

Autor: Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF

Publikováno v: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging. We analyzed the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex) in a real-world RRMM population. Median progression-free and overall s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::49c58b53c0371d5391b44a73e9011383
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9290

MECHANISM OF ACTION (MOA) OF THE ANTI-CD38 MONOCLONAL ANTIBODY ISATUXIMAB IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)

Autor: Zabaleta, A, Jelinek, T, Simoes, C, Perez, C, Prosper, F, Martinez-Cuadron, D, Bergua, JM, Vives, S, Algarra, L, Tormo, M, Martinez, P, Serrano, J, Herrera, P, Ramos, F, Salamero, O, Lavilla, E, Sanz, MA, Montesinos, P, San Miguel, JF, Paiva, B

Publikováno v: Haematologica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::368cd1a1d5b7d7bc83a6adcea35939b3
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3982

Biological and clinical signi fi cance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Autor: Maia, C, Puig, N, Cedena, MT, Goicoechea, I, Valdes-Mas, R, Vazquez, I, Chillon, MC, Aguirre, P, Sarvide, S, Gracia-Aznarez, FJ, Alkorta, G, Calasanz, MJ, Garcia-Sanz, R, Gonzalez, M, Gutierrez, NC, Martinez-Lopez, J, Perez, JJ, Merino, J, Moreno, C, Burgos, L, Alignani, D, Botta, C, Prosper, F, Matarraz, S, Orfao, A, Oriol, A, Teruel, AI, de Paz, RD, de Arriba, F, Hernandez, MT, Palomera, L, Martinez, R, Rosinol, L, Mateos, MV, Lahuerta, JJ, Blade, J, San Miguel, JF, Paiva, B

Publikováno v: Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Risk of developing myelodysplastic syndrome (MDS) is significantly increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, suggesting that it is therapy independent. However, the incidence and sequelae of dys-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9918179de2587a18ddfb1c22d801da5d
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4692